During the development of a new therapeutic, few pharmacodyamic outcomes currently receive as much scrutiny as the effect of a potential medication on the electrocardiographic QT interval. The recent withdrawal from marketing of several drugs due to potential drug-related cardiac arrhythmias have greatly increased concern about drug-related changes on the QT interval. In order to reduce the incidence of these idiosyncratic episodes, regulatory agencies have suggested that sponsors use more rigorous methodology during the safety evaluation of new pharmaceuticals. Along with enhanced electrocardiographic assessments during clinical trials, advanced preclinical examinations of effect on QT interval and ventricular repolarization have become de rigueur. In this arena, the beagle dog is the preclinical species often associated with the most reliable predictivity for human safety assessment. To this end, canine models of cardiovascular safety assessment are discussed along with the relevance of these assays to human electrocardiography.
Ackerman MJ (1998). The long QT syndrome: Ion channel diseases of the heart. Mayo Clin Proc73(3): 250—269.
2.
Aihoshi S., Yoshinga M., Nakamura M., Oku S., Haraguchi T., Nishibatake M. (1995). Screening for QT prolongation using a new exponential formula. Jpn Circ J59(4): 185—189.
3.
Albengres E. , Le Louet H., Tillement JP (1998). Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf18(2): 83—97.
4.
Anyukhovsky EP, Sosunov EA, Feinmark SJ, Rosen MR (1997). Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium: II . In vivo study. Circulation96(11): 4019—4026.
5.
Babe KS, Serafin WE (1996). Histamine, bradykinin, and their antagonists. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics , Hardman JG, Limbird LE, Molinoff PB, Ruddon RW (eds). 9th ed, McGraw-Hill, New York, p 592.
6.
Batchvarov V. , Malik M. (2002). Individual patterns of QT/RR relationship. Card Electrophysiol Rev6(3): 282—288.
7.
Bazett HC (1918). An analysis of the time-relations of electrocardiograms . Heart7: 353—370.
8.
Bers DM, Perez-Reyes E. (1999). Cachannels in cardiac myocytes: Structure and function in Ca influx and intracellular Ca release. Cardiovasc Res42(2): 339—360.
9.
Burkhart GA, Freiman J. (1995). The risk of life-threatening cardiovascular events with terfenadine [letter; comment]. Am J Cardiol75(2): 213—214.
10.
Carlsson L. , Abrahamsson C., Drews L., Duker G. (1992). Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization [see comments]. Circulation85(4): 1491—1500.
11.
Carlsson L. , Almgren O., Duker G. (1990). QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions. J Cardiovasc Pharmacol16(2): 276—285.
12.
Clarkson CW , Xu YQ, Chang C., Follmer CH (1996). Analysis of the ionic basis for cocaine's biphasic effect on action potential duration in guinea-pig ventricular myocytes. J Mol Cell Cardiol28(4): 667—678.
13.
Committee for Proprietary Medicinal Products ( 1997). The Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products.
14.
Crumb WJJ , Wible B., Arnold DJ, Payne JP, Brown AM (1995). Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: Possible mechanism for terfenadine-associated cardiotoxicity. Mol Pharmacol47(1): 181—190.
15.
Davey P. (1999). A new physiological method for heart rate correction of the QT interval. Heart82(2): 183—186.
16.
Detweiler DK (1997). Electrocardiography in toxicological studies. In: Comprehensive Toxicology, Sipes IG, McQueen CA, Gandolfi AJ (eds). Pergamon Press, New York, pp 95—114.
17.
Drolet B., Khalifa M., Daleau P., Hamelin BA, Turgeon J. (1998). Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation97(2): 204—210.
18.
Dukes ID, Cleemann L., Morad M. (1990). Tedisamil blocks the transient and delayed recitifier K+ currents in mammalian cardiac and glial cells. J Pharmacol Exp Ther254(2): 560—569.
19.
Fossa AA, DePasquale MJ, Raunig DL, Avery MJ, Leishman DJ (2002). The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment . J Pharmacol Exp Ther302(2): 828—833.
20.
Fredericia LS (1920). Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med Scan53: 469—486.
21.
Fu EY, Clemo HF, Ellenbogen KA (1998). Acquired QT prolongation: Mechanisms and implications . Cardiol Rev6(6): 319—324.
22.
Gerhardy A. , Scholtysik G., Schaad A., Haltiner R., Hess T. (1998). Generating and influencing torsades de pointes-like polymorphic ventricular tachycardia in isolated guinea pig hearts. Basic Res Cardiol93(4): 285—294.
23.
Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF (2001). The canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol37(5): 607—618.
24.
Granberry MC , Gardner SF (1996). Erythromycin monotherapy associated with torsade de pointes. Ann Pharmacother30(1): 77—78.
25.
Gras J., Llenas J. (1999). Effects of H1 antihistamines on animal models of QTc prolongation. Drug Saf Suppl 1: 39—44, 81—87.
26.
Gross DA (1994). Cardiovascular effects of inhalant anesthetic agents. In: Animal Models in Cardiovascular Research, Kluwer Academic Publishers, Dordrecht, Netherlands, pp 235—301.
27.
Gussak I., Chaitman BR, Kopecky SL, Nerbonne JM (2000). Rapid ventricular repolarization in rodents: Electrocardiographic manifestations, molecular mechanisms, and clinical insights. J Elecrocardiol33(2): 159—170.
28.
Hammond TG, Carlsson L., Davis AS, Lynch WG, MacKenzie I., Redfern WS, Sullivan AT, Camm AJ ( 2001). Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: Results of an international survey. Cardiovasc Res49(4): 741—750.
29.
Hancox JC, Levi AJ, Witchel HJ (1998). Time course and voltage dependence of expressed HERG current compared with native “rapid” delayed rectifier K current during the cardiac ventricular action potential. Pflugers Arch436(6): 843—853.
30.
Heath BM, Terrar DA (1996). Separation of the components of the delayed rectifier potassium current using selective blockers of IKr and Iks in guinea-pig isolated ventricular myocytes. Exp Physiol81(4): 587—603.
31.
International Conference on Harmonisation (1997). Guidance on Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals,
32.
International Conference on Harmonisation (2002 ). Guideline on Safety Pharmacology Studies for Human Pharmaceuticals ,
33.
International Conference on Harmonisation (2002 ). Draft Guidance on S7B Safety Pharmacology Studies for Assessing the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals,
34.
Janse MJ, Wilde AA (1998). Molecular mechanisms of arrhythmias. Rev Port Cardiol17(Suppl 2): 1141—1146.
35.
Katapadi K., Kostandy G., Katapadi M., Hussain KM, Schifter D. (1997). A review of erythromycin-induced malignant tachyarrhythmia—Torsade de pointes. A case report. Angiology48(9): 821—826.
36.
Khalifa M., Drolet B., Daleau P., Lefez C., Gilbert M., Plante S., O'Hara GE, Gleeton O., Hamelin BA, Turgeon J. (1999). Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. J Pharmacol Exp Ther288(2): 858—865.
37.
Khongphatthanayothin A., Lane J., Thomas D., Yen L., Chang D., Bubolz B. (1998). Effects of cisapride on QT interval in children. J Pediatr133(1): 51—56.
38.
Koh KK, Rim MS, Yoon J., Kim SS (1994). Torsade de pointes induced by terfenadine in a patient with long QT syndrome. J Electrocardiol27(4): 343—346.
Lecocq B., Lecocq V., Jaillon P. (1989). Physiologic relation between cardiac cycle and QT duration in healthy volunteers. Am J Cardiol64(8): 481—486.
41.
Liao WB, Bullard MJ, Kuo CT, Hsiao CT, Chu PH, Chiang CW (1996). Anticholinergic overdose induced torsade de pointes successfully treated with verapamil. Jpn Heart J37(6): 925—931.
42.
Michalets EL , Smith LK, Van Tassel ED (1998). Torsade de pointe resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother32(7—8): 761—765.
43.
Napolitano C., Priori SG, Schwartz PJ (1994). Torsade de pointes. Mechanisms and management. Drugs47(1): 51—65.
44.
O'Brien JM, Rockwood RP, Suh KI (1999). Haloperidol-induced torsade de pointes. Ann Pharmacother33(10): 1046—1050.
45.
Oberg KC, Bauman JL (1995). QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy15(6): 687— 692.
46.
Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Gerger B., Heller A. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol32: 56—67.
47.
Ometto R., Arfiero S., Vincenzi M. (1990). Torsade de pointes induced by quinidine: A case treated successfully with verapamil. G Ital Cardiol20(5): 431—434.
48.
Paris DG, Parente TF, Bruschetta HR, Guzman E., Niarchos AP (1994). Torsades de pointes induced by erythromycin and terfenadine. Am J Emerg Med12(6): 636—638.
49.
Personal Communication, Dr. Leslie Patmore (2001). Safety Pharmacology Society Meeting, Platform presentation, Chicago, IL.
50.
Piquette RK (1999). Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother33(1): 22—26.
51.
Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W., Moye L. ( 1994). Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine [see comments]. Am J Cardiol73(5): 346—352.
52.
Roden DM (1993). Torsade de pointes. Clin Cardiol16(9): 683—686.
53.
Roden DM, George ALJ, Bennett PB (1995). Recent advances in understanding the molecular mechanisms of the long QT syndrome. J Cardiovasc Electrophysiol6(11): 1023—1031.
54.
Roy M., Dumaine R., Brown AM (1996). HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine [see comments]. Circulation94(4): 817—823.
55.
Rubart M., Pressler ML, Pride HP, Zipes DP (1993). Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation88(4 Pt 1): 1832—1844.
56.
Sagie A., Larson MG, Goldberg RJ, Bengtson JR, Levy D. ( 1992). An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol70(7): 797—801.
57.
Sakemi H., VanNatta B. (1993). Torsade de pointes induced by astemizole in a patient with prolongation of the QT interval. Am Heart J125(5 Pt 1): 1436—1438.
58.
Sanguinetti MC, Jiang C., Curran ME, Keating MT (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell81(2): 299—307.
59.
Sanguinetti MC, Zou A. (1997). Molecular physiology of cardiac delayed rectifier K+ channels. Heart Vessels Suppl12: 170—172.
60.
Schulze-Bahr E., Wedekind H., Haverkamp W., Borggrefe M., Assmann G., Breithardt G., Funke H. (1999). The LQT syndromes—Current status of molecular mechanisms. Z Kardiol88(4): 245—254.
61.
Snyders DJ (1999). Structure and function of cardiac potassium channels . Cardiovasc Res42(2): 377—390.
62.
Sorota S. (1999). Insights into the structure, distribution and function of the cardiac chloride channels. Cardiovasc Res42(2): 361—376.
63.
Spence S., Soper K., Hoe CM, Coleman J. (1998). The heart rate corrected QT interval of conscious beagle dogs: A formula based on analysis of co-variance. Toxicol Sci45(2): 247—258.
64.
Van de Water A., Verheyen J., Xhonneux R., Reneman RS (1989). An improved method to correct the QT interval of the electrocardiogram. J Pharmacol Meth22(3): 207—217.
65.
Viskin S. (1999). Long QT syndromes and torsade de pointes. Lancet354(9190): 1625—1633.
Vos MA, de Groot SH, Verduyn SC, van der Zande J., Leunissen HD, Cleutjens JP, van Bilsen M., Daemen MJ, Schreuder JJ, Allessie MA, Wellens HJ (1998). Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation98(11): 1125—1135.
68.
Vos MA, Verduyn SC, Gorgels AP, Lipcsei GC, Wellens HJ (1995). Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by D-sotalol and pacing in dogs with chronic atrioventricular block [see comments]. Circulation91(3): 864—872.
69.
Walker CA, Spinale FG (1999). The structure and function of the cardiac myocyte: a review of fundamental concepts. J Thorac Cardiovasc Surg118(2): 375—382.
70.
Wang Q., Chen Q., Towbin JA (1998). Genetics, molecular mechanisms and management of long QT syndrome. Ann Med30(1): 58—65.
71.
Weissenburger J., Davy JM, Chezalviel F. (1993). Experimental models of torsades de pointes. Fundam Clin Pharmacol7(1): 29—38.
72.
WilsonWH, WeilerSJ( 1984). Casereportofphenothiazine-inducedtorsade de pointes. Am J Psychiatry141(10): 1265—1266.
73.
Woosley RL, Chen Y., Freiman JP, Gillis RA (1993). Mechanism of the cardiotoxic actions of terfenadine [see comments]. JAMA269(12): 1532— 1536.
74.
Wymore RS, Gintant GA, Wymore RT, Dixon JE, McKinnon D., Cohen IS (1997). Tissue and species distribution of mRNA for the IKr-like K+ Channel. erg. Circ Res80: 261—268.
75.
Zareba W., Moss AJ, Rosero SZ, Hajj-Ali R., Konecki J., Andrews M. (1997). Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol80(9): 1168—1173.
